BiotechTube

OP-1250

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Receptor Positive Breast Carcinoma

Conditions

Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer

Trial Timeline

Aug 13, 2020 → Jul 30, 2024

NCT ID
NCT04505826

About OP-1250

OP-1250 is a phase 1/2 stage product being developed by Olema Pharmaceuticals for Hormone Receptor Positive Breast Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04505826. Target conditions include Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Hormone Receptor Positive Breast Carcinoma were approved

Approved (5) Terminated (0) Active (15)
🔄SomatropinEli LillyPhase 3
🔄Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
🔄Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
🔄Enzalutamide + PlaceboAstellas PharmaPhase 3
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
🔄PEG-somatropinSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04505826Phase 1/2Completed

Competing Products

20 competing products in Hormone Receptor Positive Breast Carcinoma

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
44
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
YM598Astellas PharmaPhase 2
27
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
35
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
50
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29